Market Place
Sourcing Support
1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL
10 Dec 2024 //
PR NEWSWIRE
Olverembatinib Data Reaffirms Potential in Ponatinib Resistance
10 Dec 2024 //
PR NEWSWIRE
Olverembatinib Overcomes CML Resistance, Well Tolerated in Report
21 Nov 2024 //
PR NEWSWIRE
ASH 2024: Olverembatinib Data Selected for Oral Presentation
06 Nov 2024 //
PR NEWSWIRE
Ascentage Pharma Releases Olverembatinib Data In SDH-Deficient GIST
13 Sep 2024 //
PR NEWSWIRE
Olverembatinib Approved for Commercialization in Macau China
07 Jul 2024 //
PR NEWSWIRE
Ascentage Pharma Received US$100 Million Option Payment from Takeda
03 Jul 2024 //
PR NEWSWIRE
EHA 2024: Olverembatinib Studies Show Encouraging Data In CML And Ph+ ALL
18 Jun 2024 //
PR NEWSWIRE
Takeda Signs Option With Ascentage For Olverembatinib License
14 Jun 2024 //
BUSINESSWIRE
China NMPA approves Ascentage Pharma’s phase III study of olverembatinib
12 Jun 2024 //
PHARMABIZ
China Approves Phase 3 Trial Of Olverembatinib For SDH-Deficient GIST
10 Jun 2024 //
PR NEWSWIRE
Olverembatinib: 92.3% CBR In SDH-Deficient GIST Per ASCO 2024 Report
04 Jun 2024 //
PR NEWSWIRE
Ascentage releases latest results from multiple clinical studies of lead drug
25 May 2024 //
INDIANPHARMAPOST
Ascentage Presents 4 Studies, Olverembatinib GIST Data at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
Global Registrational Phase III Study of Olverembatinib Cleared by FDA
13 Feb 2024 //
PR NEWSWIRE
Olverembatinib Included in Newest Guidelines on CML Management from NCCN
16 Jan 2024 //
PR NEWSWIRE
Oral Report Featuring Data of Olverembatinib in Patients with Ph+ ALL Presented
14 Dec 2023 //
PR NEWSWIRE
Results from Studies of Olverembatinib Presented in Oral Report at the ASH
13 Dec 2023 //
PR NEWSWIRE
Ascentage Pharma Presents Updated Data from US Study of Olverembatinib
11 Dec 2023 //
PR NEWSWIRE
Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib
24 Nov 2023 //
PR NEWSWIRE
Results from Studies of Olverembatinib Have Been Selected for Presentations
02 Nov 2023 //
PR NEWSWIRE
First Patient Dosed in the Registrational Phase III Study of Olverembatinib
17 Oct 2023 //
PR NEWSWIRE
Registrational PIII Study of Olverembatinib for First-Line Treatment of Ph+ ALL
05 Jul 2023 //
PR NEWSWIRE
Innovent Announces the Second Breakthrough Therapy Designation for Olverembatinib
02 Jun 2023 //
PR NEWSWIRE
Ascentage `s Novel Drug Olverembatinib Recommended for a Breakthrough Therapy
30 May 2023 //
PR NEWSWIRE
Innovent Announces Inclusion in the China NRDL of TYVYT in Two New Indications
18 Jan 2023 //
PR NEWSWIRE
Olverembatinib Included into the 2022 National Reimbursement Drug List
18 Jan 2023 //
PR NEWSWIRE
Ascentage Pharma Delivers Oral Report on the First Dataset from HQP1351
11 Dec 2022 //
PRNEWSWIRE
Ascentage to Present Data of Olverembatinib in Three Oral Reports
03 Nov 2022 //
PRNEWSWIRE
Ascentage Announces Phase I/II Data of Olverembatinib Published in the Journal
21 Sep 2022 //
PRNEWSWIRE
NMPA Grants Priority Review to Innovent and Ascentage`s NDA for Olverembatinib
19 Jul 2022 //
PRNEWSWIRE
First Dataset of Olverembatinib in with GIST Demonstrates Therapeutic Potential
06 Jun 2022 //
PRNEWSWIRE
Ascentage Pharma launches new groundbreaking drug for CML
20 Dec 2021 //
CHINADAILY
Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib
14 Dec 2021 //
PRNEWSWIRE
Ascentage`s Olverembatinib Granted ODD by EC for CML
22 Nov 2021 //
PRNEWSWIRE
ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib
04 Nov 2021 //
PRNEWSWIRE
Ascentage Announces Positive Data from Pivotal Phase II Studies of HQP1351
07 Dec 2020 //
PRNEWSWIRE
